Yet more justification, if any were needed that the UK NHS needs to seriously look into widespread use of Low Dose Naltrexone (LDN) as a low cost treatment for Crohn's Disease, Ulcerative Colitis and the any other conditions it has been used successfully to reat including other auto-immune disease, cancers, autism and HIV/AIDs.
At £12,500 per patient per year for Infliximab versus £300 per year for Low Dose Naltrexone, it is the proverbial 'no-brainer' for the NHS to do whatever it takes to convince consultants and GPs that LDN is a suitable drug choice for IBD.
The government and public bodies need to cease dithering on this and take action now so that IBD sufferers need not suffer unnecessarily.
http://bit.ly/NICEIBD
Saturday, 12 December 2009
Subscribe to:
Post Comments (Atom)
Posts
Well said Bob, who is running this country that they cannot work that out for themselves??
ReplyDeleteIt's a sad reflection on todays'society.......
Celia
Bob,
ReplyDeleteQuite correct!
By the way, please correct the above "(Typically 1/50)" to read "Typically less than 1/10)".